A description of these risks and uncertainties can be found in Pfizer’s most recent Annual Report on Form 10-K and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. Investor Contact: Ryan Crowe (212) 733-8160 Media Contact: Patricia Kelly (212) 733-3810. Dividend Summary. This rating is reserved for companies with strong balance sheets and/or excellent dividend histories. Pfizer is one of the world’s largest pharmaceutical firms, with annual sales over $50 billion. This represents an 5.88% increase over prior dividend payment. Patricia Kelly DISCLOSURE NOTICE: The information contained in this release is as of December 14, 2018. Invest With Confidence In Less Time - Manage Your Portfolio Without Behavioral Errors. The company has a large diversified portfolio of drugs and a sustaining pipeline of new drugs. For more than 150 years, we have worked to make a difference for all who rely on us. Pfizer also spends a leading amount on research and development, close to $8 billion annually. Pfizer Declares Third-Quarter 2019 Dividend, MAINTAINING EMOITONAL WELLBEING DURING COVID-19, CORONAVIRUS DISEASE (COVID-19) SCIENTIFIC RESOURCES. Pfizer’s global salesforce and patent-protected drugs produce large amounts of cash flow.

Pfizer is being squeezed from three angles.Drug approval authorities are becoming more risk adverse.Buyers are consolidating to increase their purchasing power and demanding lower margins.Changes in healthcare insurance are putting downward pressure on prices. nodes[i].dataset.subscription : nodes[i].getAttribute('data-subscription'); if(status ==='true') {nodes[i].checked = true;}}};var nodes = document.querySelectorAll('#form1783 select[data-value]'); if (nodes) { for (var i = 0; i < nodes.length; i++) { var node = nodes[i]; var selectedValue = node.dataset ? In particular, the loss of Viagra (2017) and Lyrica (2019) have been large challenges for the company. A blog in the Arbor Investments Planner Network. )+[a-z]{2,63}/i);}, failureMessage: "Value must not contain any URL's"});field11.add(Validate.Presence, {failureMessage:"This field is required"});field11.add(Validate.Length, {tooShortMessage:"Invalid length for field value", tooLongMessage: "Invalid length for field value", minimum: 4, maximum: 4});function handleFormSubmit(ele) { var submitButton = ele.querySelector('input[type=submit]'); var spinner = document.createElement('span'); spinner.setAttribute('class', 'loader'); submitButton.setAttribute('disabled', true); submitButton.style.cursor = 'wait'; submitButton.parentNode.appendChild(spinner); return true; }function resetSubmitButton(e){ var submitButtons = e.target.form.getElementsByClassName('submit-button'); for(var i=0;i

Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. Pfizer Declares First-Quarter 2019 Dividend, Therapeutic Modalities and Technology Platforms, Small Molecule Product & Process Development, Maintaining Emotional Well-Being During COVID-19, Coronavirus disease (COVID-19) Scientific Resources, Meet our new Chief Patient Officer, Dr. Dara Richardson-Heron, Creating Cures Through Facility Investments. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. A grade indicates a quality company with a strong balance sheet, high earnings quality, and a positive business environment. Pfizer Declares Third-Quarter 2019 Dividend, Therapeutic Modalities and Technology Platforms, Small Molecule Product & Process Development, Maintaining Emotional Well-Being During COVID-19, Coronavirus disease (COVID-19) Scientific Resources, Meet our new Chief Patient Officer, Dr. Dara Richardson-Heron, Creating Cures Through Facility Investments.

The Pfizer dividend has been paid since 1980 and has increased the dividend for 9 consecutive years; qualifying the company as a Dividend Challenger. C grade indicates a company with a sufficient balance sheet, at least average earnings quality, and a reasonably stable business environment. About Pfizer: Working together for a healthier world®. patents), economies of scale, and an impressive distribution network provide a wide moat. Media Contact:Patricia Kelly(212) 733-3810, Investor Contact:Ryan Crowe(212) 733-8160. Pfizer increased the dividend by approximately 6 percent, to 36 cents from 34 cents per … The Board of Directors of Pfizer Inc. today declared a 36-cent third-quarter 2019 dividend on the company’s common stock, payable September 3, 2019, to holders of the Common Stock of record at the close of business on August 2, 2019. The Company assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments. Top sellers include pneumococcal vaccine Prevnar 13, neuroscience drug Lyrica, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drugs Enbrel and Xeljanz. This webcast may contain forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candidates, strategic reviews, capital allocation, business-development plans, the benefits expected from the reorganization of our commercial operations into three businesses effective at the beginning of our 2019 fiscal year, our acquisitions and other business development activities, our proposed transaction with GSK to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture, our ability to successfully capitalize on growth opportunities or prospects, manufacturing and product supply and plans relating to share repurchases and dividends, among other things, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. The Board of Directors of Pfizer Inc. today declared a 36-cent third-quarter 2019 dividend on the company’s common stock, payable September 3, 2019, to holders of the Common Stock of record at the close of business on August 2, 2019.

https://www.businesswire.com/news/home/20190627005855/en/, Investor Contact: D grade indicates earnings quality is poor and requires thoughtful due diligence. Ryan Crowe The majority of Pfizer’s revenues come from a highly regulated and extremely competitive industry. PFE was founded in 1942, and is based in New York. The first-quarter 2019 cash dividend will be the 321st consecutive quarterly dividend paid by Pfizer.

In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. Pfizer’s strong position in the industry makes it a great partner for smaller drug companies that don’t have the resources to go it alone. PFE used to be a Dividend Aristocrat until it cut its dividend during the great recession. This has provided high returns on invested capital and allowed the company to return significant cash to shareholders. The margin of safety required is greater than A & B stocks, but less than D & F stocks.